Get the Stockscreener App
3.83
1.32%
0.05
Pre-market:
4.07
0.24
+6.27%
Adc Therapeutics Sa stock is traded at $3.83, with a volume of 978.63K.
It is up +1.32% in the last 24 hours and up +0.79% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$3.78
Open:
$3.78
24h Volume:
978.63K
Relative Volume:
1.13
Market Cap:
$487.14M
Revenue:
$81.36M
Net Income/Loss:
$-142.62M
P/E Ratio:
-3.1893
EPS:
-1.2009
Net Cash Flow:
$-146.97M
1W Performance:
-2.79%
1M Performance:
+0.79%
6M Performance:
-14.13%
1Y Performance:
+167.83%
1-Day Range:
$3.72
$3.845
1-Week Range:
$3.665
$4.09
52-Week Range:
$1.225
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.83 | 487.14M | 81.36M | -142.62M | -146.97M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - Yahoo Finance Australia
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - ChartMill
MSN Money - MSN
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday - MarketBeat
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 - Nasdaq
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
ADC Therapeutics rises on $60M PIPE financing - MSN
ADC Therapeutics schedules May 4 webcast on Q1 results and operations - Stock Titan
Redmile Group (NASDAQ: ADCT) reports 9.9% stake after SPV reorg - Stock Titan
ADC Therapeutics S.A. Investigated by the Portnoy Law Firm - GlobeNewswire
ADC Therapeutics SA ($ADCT) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay, equity plan and capital changes at ADC Therapeutics (ADCT) - Stock Titan
ADC Therapeutics (NASDAQ: ADCT) adds SILV Fund as selling shareholder - Stock Titan
ADC Therapeutics (NYSE:ADCT) Shares Up 11.8%Still a Buy? - MarketBeat
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update - ADVFN
ADC Therapeutics (NYSE: ADCT) to hold virtual AGM June 1; votes on capital and pay - Stock Titan
Aug Spikes: Can ADC Therapeutics SA continue delivering strong returns2026 Key Lessons & High Accuracy Trade Signal Alerts - baoquankhu1.vn
ADC Therapeutics SA $ADCT Stock Holdings Raised by JPMorgan Chase & Co. - MarketBeat
ADCT.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ADCT.N Technical Analysis & Stock Price Forecast - Intellectia AI
Redmile Group, Jeremy Green disclose 9.99% stake in ADC Therapeutics (ADCT) - Stock Titan
Risk Off: Does ADC Therapeutics SA have a sustainable dividendWeekly Profit Analysis & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Insider Sell: What is the implied volatility of ADC Therapeutics SA2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
ADCT News & Events - Intellectia AI
ADCT Should I Buy - Intellectia AI
ADCT.N PE Ratio & Valuation, Is ADCT.N Overvalued - Intellectia AI
Next Generation Drug Conjugates (NDCs) Market Worth $42.55 Billion by 2035 | MarketsandMarkets - 富途牛牛
ADCT Stock Analysis: ADC Therapeutics SA Common Shares at $3.78 after 0.53pct dip - Cổng thông tin điện tử Tỉnh Sơn La
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells $8,641,179.68 in Stock - MarketBeat
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells 196,229 Shares of Stock - MarketBeat
Redmile-managed funds trim ADC Therapeutics (ADCT) stake with 5.9M-share sale - Stock Titan
ADC Therapeutics Announces New Employee Inducement Grant - Financial Times
Energy Moves: Is ADC Therapeutics SA in a consolidation phase2026 Retail Activity & Real-Time Volume Spike Alerts - baoquankhu1.vn
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Nasdaq Moves: Is ADC Therapeutics SA a stock for growth or value investors2026 Setups & High Accuracy Buy Signal Tips - baoquankhu1.vn
ADC Therapeutics Eyes ZYNLONTA Expansion as LOTIS-5 Data Nears at H.C. Wainwright Chat - MarketBeat
ADC Therapeutics (NYSE:ADCT) Shares Gap Up on Analyst Upgrade - Defense World
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 - MarketBeat
ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028 - Yahoo Finance
US Stocks Recap: Can ADC Therapeutics SA disrupt its industryRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Heights Capital Management Inc. Has $1.31 Million Position in ADC Therapeutics SA $ADCT - MarketBeat
Growth Recap: Will ADC Therapeutics SA benefit from rate cuts2026 Dividend Review & Technical Entry and Exit Tips - baoquankhu1.vn
Fed Watch: Is ADC Therapeutics SA stock showing strong momentumMarket Rally & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
[EFFECT] ADC Therapeutics SA SEC Filing - Stock Titan
ADC Therapeutics (ADCT) registers 9.83M shares issuable on HCR warrants - Stock Titan
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):